Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, a growth of 17.9% from the November 15th total of 1,230,000 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily volume of 487,900 shares, the days-to-cover ratio is currently 3.0 days.

Compass Therapeutics Price Performance

CMPX stock traded up $0.06 during trading on Monday, reaching $1.52. 84,147 shares of the company were exchanged, compared to its average volume of 438,212. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The company has a market capitalization of $209.14 million, a price-to-earnings ratio of -4.07 and a beta of 0.89. The company has a 50-day moving average of $1.68 and a two-hundred day moving average of $1.41.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. On average, analysts forecast that Compass Therapeutics will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Compass Therapeutics by 10.3% in the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares during the last quarter. Rovin Capital UT ADV bought a new position in shares of Compass Therapeutics during the third quarter valued at about $25,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics during the third quarter worth about $30,000. Finally, Geode Capital Management LLC grew its position in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on CMPX shares. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, November 11th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Finally, Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.